Kymera Therapeutics launches $500M ATM program

Kymera Therapeutics, Inc. established an at-the-market stock offering program allowing it to sell up to $500,000,000 of common shares through TD Securities (USA) LLC, which will act on a best efforts basis for sales on Nasdaq and other permitted methods.

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. established an at-the-market stock offering program allowing it to sell up to $500,000,000 of common shares through TD Securities (USA) LLC, which will act on a best efforts basis for sales on Nasdaq and other permitted methods.

The company will pay TD Cowen a commission of up to 3.0% of gross proceeds and may start, pause, or terminate sales at its discretion. Separately, Kymera filed a resale prospectus supplement registering the potential resale by certain existing investors of up to 18,819,826 outstanding common shares and 12,565,253 shares issuable upon exercise of pre-funded warrants at an exercise price of $0.0001 per warrant. Kymera will not receive proceeds from any resale of these shares, and will receive cash only if the warrants are exercised for cash.

8-K Event Classification

4 items: 1.01, 1.02, 8.01, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kymera Therapeutics (KYMR) announce in this 8-K filing?

Kymera Therapeutics launched a new at-the-market stock offering program of up to $500,000,000 in common shares through TD Securities (USA) LLC and filed a resale prospectus supplement covering potential share sales by existing investors, without issuing new securities under that resale supplement.

How large is Kymera Therapeutics’ new at-the-market offering program?

The at-the-market program permits Kymera to sell up to $500,000,000 of its common stock. Sales may occur from time to time on Nasdaq or through other methods deemed at-the-market offerings under Rule 415, at Kymera’s sole discretion, via TD Cowen on a best efforts basis.

What fees will Kymera Therapeutics pay under the TD Cowen sales agreement?

Kymera will pay TD Securities (USA) LLC a commission of up to 3.0% of the gross proceeds from any common shares sold under the at-the-market program. This commission applies only to shares actually sold, since Kymera is not obligated to sell any specific amount.

What resale shares did Kymera Therapeutics register for existing stockholders?

Kymera registered the potential resale of up to 18,819,826 outstanding common shares plus 12,565,253 shares issuable upon exercise of pre-funded warrants. These securities are held by specified selling stockholders under a registration rights agreement, and the filing itself does not represent an actual sale.

Will Kymera Therapeutics receive proceeds from the resale of registered shares?

Kymera will not receive any proceeds if selling stockholders resell the registered common shares or warrant shares. The company would receive cash only upon any cash exercise of the pre-funded warrants at an exercise price of $0.0001 per warrant; cashless exercises would provide no proceeds.

What happened to Kymera Therapeutics’ prior open market sale agreement?

Jefferies LLC acknowledged and accepted Kymera’s written notice terminating their prior Open Market Sale Agreement, originally dated October 31, 2024. The termination became effective immediately, clearing the way for Kymera’s new at-the-market offering program with TD Securities (USA) LLC as sales agent.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 08:22 AM Learn about SEC filing dates

false 0001815442 0001815442 2026-02-26 2026-02-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 26, 2026

KYMERA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39460		81-2992166
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kymera Therapeutics, Inc.

500 North Beacon Street, 4th Floor

Watertown, Massachusetts 02472

(Address of principal executive offices, including zip code)

(857) 285-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trade Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KYMR		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry Into a Material Definitive Agreement.

On February 26, 2026, Kymera Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “TD Cowen Sales Agreement”), with TD Securities (USA) LLC (“TD Cowen”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at the Company’s sole discretion, shares of the Company’s common stock, having an aggregate offering price of up to $500,000,000 (the “Shares”), through TD Cowen. The issuance and sale, if any, of the Shares may be by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act of 1933 (the “Securities Act”), including, without limitation, sales made directly on the Nasdaq Global Market, or Nasdaq.

The Company is not obligated to sell any of the Shares, and TD Cowen is not required to sell any specific number or dollar amount of the Shares under the TD Cowen Sales Agreement. The Company or TD Cowen may suspend or terminate the offering of the Shares upon notice to the other party and subject to other conditions.

Subject to the Company’s request to sell the Shares, TD Cowen will act on a best efforts basis and use commercially reasonable efforts to sell the Shares on the Company’s behalf, from time to time consistent with its normal sales practices and applicable state and federal laws, rules and regulations and Nasdaq rules, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay TD Cowen a commission of up to 3.0 percent (3.0%) of the gross proceeds of any of the Shares sold through TD Cowen under the TD Cowen Sales Agreement. Pursuant to the TD Cowen Sales Agreement, the Company has also provided TD Cowen with customary indemnification and contribution rights.

Any Shares to be offered and sold under the TD Cowen Sales Agreement will be issued and sold pursuant to the Company’s Registration Statement on Form S-3ASR (File No. 333-282912) (the “Registration Statement”), which was filed with the Securities and Exchange Commission (“SEC”) on October 31, 2024 and became automatically effective upon filing pursuant to Rule 462(e) of the Securities Act. The Company filed a prospectus supplement, dated February 26, 2026, with the SEC in connection with the offer and sale of the Shares pursuant to the TD Cowen Sales Agreement.

The foregoing description of the TD Cowen Sales Agreement is not complete and is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Goodwin Procter LLP, counsel to the Company (“Goodwin”), has issued an opinion to the Company, dated February 26, 2026, relating to the validity of the Shares to be issued and sold pursuant to the TD Cowen Sales Agreement, a copy of which is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 1.02 Termination of a Material Definitive Agreement.

On February 26, 2026, Jefferies LLC (“Jefferies”) acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sale Agreement^SM, dated as of October 31, 2024, by and between the Company and Jefferies, effective immediately.

Item 8.01 Other Events.

Pursuant to the terms of the Registration Rights Agreement, dated as of June 26, 2025, by and among the Company, Baker Brothers Life Sciences, L.P. and 667, L.P., entities affiliated with Atlas Venture and entities affiliated with BVF Partners L.P (the “Selling Stockholders”), which, among other things, provided the Selling Stockholders with certain “resale” registration rights, the Company filed a prospectus supplement on February 26, 2026 (the “Resale Prospectus Supplement”) with the SEC solely to register the potential resale by the Selling Stockholders of up to an aggregate of (i) 18,819,826 shares of the Company’s common stock, par value $0.0001 per share (the “Resale Shares”) and (ii) 12,565,253 shares of common stock issuable upon the exercise of pre-funded warrants to purchase shares of the Company’s common stock, at an exercise price equal to $0.0001 per pre-funded warrant (the “Resale Warrant Shares”).

The filing of the Resale Prospectus Supplement is not itself a sale of securities by the Selling Stockholders and does not necessarily mean that the Selling Stockholders will choose to sell any Resale Shares or Resale Warrant Shares. If any Resale Shares are sold by the Selling Stockholders, the Company would not receive any proceeds from that sale. Upon any cash exercise of Resale Warrant Shares by the Selling Stockholders, the Company would receive cash proceeds per share equal to the exercise price of the exercised Resale Warrant Shares. If the Resale Warrant Shares are exercised in a cashless exercise, the Company will not receive any proceeds from the exercise of the Resale Warrant Shares. No securities will be issued or sold by the Company pursuant to the Resale Prospectus Supplement.

The Resale Prospectus Supplement was filed pursuant to the Registration Statement.

Goodwin has issued an opinion to the Company, dated February 26, 2026, relating to the validity of the Resale Shares and Resale Warrant Shares covered by the Resale Prospectus Supplement, a copy of which is filed as Exhibit 5.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
5.1		Opinion of Goodwin Procter LLP.
5.2		Opinion of Goodwin Procter LLP.
10.1		Sales Agreement, by and between Kymera Therapeutics, Inc. and TD Securities (USA) LLC, dated February 26, 2026.
23.1		Consent of Goodwin Procter LLP (included in Exhibit 5.1).
23.2		Consent of Goodwin Procter LLP (included in Exhibit 5.2).
104		Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Kymera Therapeutics, Inc.
Date: February 26, 2026				By:		/s/ Nello Mainolfi
						Nello Mainolfi, Ph.D.
						President and Chief Executive Officer

Filing Exhibits & Attachments

6 documents

Agreements & Contracts

• EX-10.1 EX-10.1 178.0 KB

Other Documents

• EX-5.1 EX-5.1 7.0 KB
• EX-5.2 EX-5.2 6.9 KB
• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB